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Background: Infliximab has shown benefit in Crohn’s disease (CD) and ulcerative colitis (UC).
Objective: Evaluation of long-term outcome of therapy for both diseases.
Methods: We analyzed retrospectively patients treated at infusion centers from one institution. 
Demographic, laboratory parameters leading up to biologic therapy and the subsequent pattern 
of outcomes in either disease were established as a database. Initial failure, subsequent need 
to change therapy, or need to adjust therapy were evaluated. Kruskal–Wallis (nonparametric) 
tests to compare two groups and Kaplan–Meier survival curve analysis were used to compare 
outcomes.
Results: Over approximately 6 years, 71 CD and 26 UC patients received 999 and 215   infusions, 
respectively, for a median of 62 months. Of these, 17% for CD and 19% for UC patients were 
primary failures. Following the start of infliximab, 18% of CD and 11% of UC patients required 
stoppage and switching to another type of therapy. In either CD or UC patients, 54% or 62%, 
respectively, continued therapy without the need to change to other treatments. Few serious 
side effects were noted. No important statistically significant differences in treatment patterns 
or outcome were observed between the groups.
Discussion: Long-term treatment of both inflammatory bowel diseases reflects outcomes of 
clinical trials.
Conclusions: This study emphasizes similarities between CD and UC and reports therapeutic 
success for an extended time.
Keywords: infliximab, inflammatory bowel diseases
Introduction
The description of cell signaling inflammatory cytokine cascades in the past two 
decades has led to the development of novel biological therapies, especially in the 
inflammatory bowel diseases (IBDs) Crohn’s disease (CD) and idiopathic ulcerative 
colitis (UC). Initially, CD was considered to be a predominantly type 1 T helper (Th1) 
and UC a Th2 cytokine cascade-mediated disease.1–4 Therefore, infliximab (IFX), 
which is an immunoglobulin G1 (IgG1)-based chimeric mouse–human monoclonal 
antitumour necrosis factor alpha (TNFα) antibody, was primarily approved for tar-
geting CD. However, TNFα was found in significant quantities in serum, stool, and 
colonic mucosa of patients with active UC.5–8 Although a number of smaller clinical 
studies reported conflicting results in UC,9–12 analysis of a number of studies confirmed 
the role of IFX in this disease as well.13
ACCENT (A Crohn’s Disease Clinical Trial Evaluating Infliximab in a New 
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  maintenance, and fistulizing CD.14,15 The Active Ulcerative 
Colitis Trial (ACT I) and ACT II also established its use in 
UC.16 The overall use of IFX for CD has now passed beyond 
a decade of experience. In Canada, approval for UC of this 
agent is now over 4 years old. Previous utilization of IFX in 
UC required special requests for humanitarian purposes.
Although randomized trials are important instruments 
in establishing the use of any agent in diseases, it is also 
very important to evaluate whether agents in use achieve 
  expectations in clinical practice. In an effort to compare 
clinical outcomes, we evaluated the effects of IFX on CD 
and UC over a period of 6 years from a single center.
Methods
We retrospectively evaluated patients from infusion clinics 
that serve outpatients referred from hospitals. We included 
only those patients from our institution who were treated at 
these centers between January 2002 and April 2008. Some 
patients during this period were started in the previous 
2 years at the hospital itself and then transferred to infusion 
clinics.
Ethics Review Board approval from the Jewish   General 
Hospital was obtained, and the charts of patients were 
reviewed by two of the authors (RA and PM). A database 
was established using information abstracted from charts. 
Diagnoses of CD and UC conformed to accepted criteria.17
Relevant information was obtained, including type of 
disease, age, sex, time of disease prior to IFX therapy, and 
location of CD (terminal ileum and colon, colon only, or 
ileum/small bowel only) or UC (left or total colitis). Smoking 
history was poorly recorded and therefore omitted.
Laboratory data were recorded for three periods to assess 
changes: after diagnosis up to 1 month prior to IFX therapy 
(general period), within 1 month prior to IFX therapy, and 
anytime after receiving IFX therapy. Parameters recorded 
include hemoglobin, white blood cells, platelet count, mean 
platelet volume, lymphocyte number and percentage, poly-
morphonuclear leukocytes, C-reactive protein, albumin, total 
iron-binding capacity, percent saturation, and ferritin.
Relevant therapeutic data before IFX were recorded for 
two periods: general period and 1 month prior to   infusion. 
We listed therapy in categories of increasing order. In 
this scheme, 0 = no therapy, 1 = 5-acetylsalicylic acid, 
2 =   prednisone, 3 = first-line immunomodulators azathioprine/ 
6-mercaptopurine or methotrexate, 4 =   second-line immuno-
modulators cyclosporine A or mycophenolate mofetil, and 
5 = previous IFX more than 1 year earlier within the limits 
of the study period. Information on the intake of medications 
other than IFX after the start of infusion was recorded incon-
sistently and was therefore omitted from analysis. However, 
previous surgical interventions and the presence of external 
fistulae were recorded. Characteristics of IFX therapy were 
tabulated separately, including results of a purified protein 
derivative test, the starting dose,   physician’s indication for 
IFX, and side effects.
Definitions
Indications for IFX treatment included severity of disease 
defined by physician’s opinion as stated on the request for IFX 
application. Other indications were control of fistulae with or 
without aggravated clinical disease or other reasons.
Therapeutic markers and follow-up times in the study 
were defined by the length of treatment. Primary nonre-
sponders were defined as any patient receiving three or fewer 
infusions, excluding those with an episodic form of treatment. 
These patients remained symptomatic with diarrhea, pain, 
or continued blood loss.
The median length of follow-up was also defined by 
the median length of treatment. Duration of response was 
reflected in the time between the first dose (induction phase) 
and the last dose and is based on similar definitions used 
elsewhere.18 Those patients continuing therapy were less 
symptomatic and were considered to be in remission by their 
physicians. Thus, continued therapy at the end of the observa-
tion period was chosen as a surrogate marker of successful 
maintenance or failure to relapse. No attempt was made to 
evaluate endoscopic outcome.
Outcome of therapy failure was divided into two types. 
Grade A failure included a loss of response with increased 
symptoms resulting in an altered form of therapy, such as 
surgery, switch to other biologics in the same class, switch 
to other nonbiologic therapy, or side effects. Grade B failure 
indicates a loss of response with a requirement for changing 
frequency or dose of IFX.
Some patients stopped IFX because of miscellaneous 
  reasons. These are included in the results and are not 
  considered a failure of therapy.
Statistical analysis
Analyses were conducted using Intercooled Stata 8.2 
  statistical software (StataCorp, College Station, TX, USA). 
A Chi-square test was used to examine the association in 
two-way tables between disease type and another categorical 
variable, such as line of treatment; Fisher’s exact test was Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Table  1  Demographic  features  of  71  patients  with  Crohn’s 
disease (CD) and 26 with idiopathic ulcerative colitis (UC). Data 
are listed for time-dependent variables as prior to infliximab (iFX) 
infusion. “General” refers to any time up to 1 month   pre-iFX. 
Marginally  significant  differences  were  noted  for  fistulae  by 
disease type (exact P = 0.06) and surgery before iFX by disease 
type  (exact  P  =  0.09).  no  other  differences  were  statistically 
significant
Crohn’s 
disease 
(n = 71)
Idiopathic 
ulcerative colitis 
(n = 26)
Mean (SD)
Age 38.9 (13.1) 38.4 (13.9)
Time to disease (years before iFX) 8.7 (8.1) 6.3 (6.4)
n (%)
Gender
  Female 35 (49%) 14 (54%)
  Male 36 (51%) 12 (46%)
Location
  small bowel only (in CD) 19 (27%) n/a
  Terminal ileum and colon (in CD) 29 (41%) n/a
  Colon only (in CD) 23 (32%) n/a
  Left-sided only (in UC) n/a 8 (31%)
  Pancolitis (in UC) n/a 16 (62%)
  Pouchitis (in UC) n/a 2 (8%)
Fistulae 15 (21%) 1 (4%)a
Level of medical therapy (0–5)
General pre-iFXb
  0: none 16 (23%) 8 (31%)
  1: 5-Aminosalacylic acid 10 (14%) 5 (19%)
  2: Prednisone 40 (56.3%) 13 (50%)
  3:   Azathioprine/6-mercaptopurine 
or methotrexate
26 (36.6%) 8 (30.8%)
  4:   Cyclosporine or mycophenylate 
mofetil
1 (1%) 0 (0%)
  5: Biologic therapy 2 (3%) 1 (4%)
1 month pre-iFX
  0: none 7 (10%) 1 (4%)
  2: Prednisone 46 (64.8%) 23 (88.5%)
  3:   Azathioprine/6-mercaptopurine  
or methotrexate
59 (83.1%) 21 (80.1%)
surgical therapy, general pre-iFX 17 (24%) 2 (8%)
Notes: aOne patient, 6 years after colectomy for UC, developed a rectovaginal 
fistula. Despite suspicion of CD as the true nature of cause, no radiological or 
histological  evidence  was  found  to  support  CD.  she  was  considered  to  have 
pouchitis. bTreatment levels are not mutually exclusive.
used if any expected cell count was less than 5.   Comparisons 
of continuous numerical variables by disease type were 
calculated using a two-group t-test, assuming equal or 
unequal variances as appropriate. When continuous variables 
appeared to be non-normally distributed, a nonparametric 
Kruskal–Wallis (K–W) test was used to test for differences 
between disease groups.
Length of time, such as the length of disease prior to IFX 
therapy, was observed for all patients and analyzed using a 
K–W test for differences in medians. Length of time, such 
as the time to treatment deterioration and length of treat-
ment, was not observed for all patients (because the events 
of deterioration and end of treatment could occur after the 
observed study period), so these values were handled as 
either observed or censored and survival analysis methods 
were applied. Nonparametric Kaplan–Meier survival curves 
were plotted for time until treatment deterioration and length 
of treatment by disease groups. Differences between the 
  survival curves were examined using a log-rank test. All tests 
were two-tailed and alpha was set at P = 0.05 for statistical 
significance.
Three patients with indeterminate colitis were treated as 
having CD for the analysis.
Results
Ninety-seven patients (71 patients with CD [50% male] and 
26 with diagnosis of UC [43% male]) were infused during the 
observation period. Demographic features of the patients are 
displayed in Table 1. The distribution of CD across disease 
sites followed expectations, and the majority of patients 
with UC had pancolitis. Seventeen (24%) CD and two (8%) 
UC patients underwent surgery anytime prior to IFX. Two 
patients with previous colectomy for UC had pouchitis, and 
one of these developed a resistant rectovaginal fistula. Of the 
CD patients, 15 (21%) had a variety of fistulae that failed 
medical or surgical therapy. Two CD patients who tested 
positive for tuberculosis were treated prophylactically.
In each group, over 40% received corticosteroids 
  generally. By 1 month prior to IFX, almost two-thirds 
of CD and 90% of UC patients received corticosteroids. 
Overall, in CD, nine (16%) did not respond (corticosteroid 
  resistant) and six (11%) could not discontinue corticosteroids 
(  corticosteroid dependent). In the case of UC, the outcome 
was seven (33%) and one (5%), respectively. None of the 
comparisons was significant.
Azathioprine, 6-mercaptopurine, or methotrexate 
(11/71 in CD, 15.5%) were used in about a third in either 
CD or UC patients in general. However, by 1 month prior to 
IFX use, over 80% were using immunomodulators in both 
diseases. Immunomodulators were continued throughout 
with episodic IFX use.
Table 2 outlines a summary of laboratory data obtained 
for CD and UC patients generally, 1 month before, and at 
some point within about 1 year after starting IFX therapy. 
Only two laboratory variables were found to be significantly 
different between CD and UC. One month prior to IFX Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Laboratory values for patients with Crohn’s disease (CD) or idiopathic ulcerative colitis (UC). Values are listed as during 
a general period, 1 month prior to infliximab (iFX) infusion, and general after iFX infusion. sample sizes are noted for each statistic. 
Mean values are provided. Bracketed values represent sD
Laboratory values General pre-IFX 1 month pre-IFX General post-IFX
CD UC CD UC CD UC
hgb (g/L) n = 43 
126.6 
(19.2)
n = 14 
120.7 
(13.2)
n = 66 
129.1a 
(18.1)
n = 26 
120.0a 
(18.3)
n = 60 
135.1 
(19.1)
n = 23 
133.9 
(16.7)
WBC (x10E9) n = 43 
8.9 
(3.9)
n = 13 
7.8 
(2.8)
n = 66 
13.7 
(40.4)
n = 26 
9.9 
(4)
n = 60 
8.4 
(3.8)
n = 23 
19.2 
(58.2)
Platelets (x10E9) n = 43 
329.7 
(92.5)
n = 13 
357.5 
(168.7)
n = 66 
340.8 
(115.7)
n = 26 
366.8 
(94.5)
n = 60 
291.3 
(104.4)
n = 23 
310.7 
(129.1)
MPV (fL) n = 40 
9.1 
(2.1)
n = 12 
9.5 
(1.7)
n = 65 
9.8 
(3.4)
n = 22 
9.2 
(1.8)
n = 58 
10.7 
(4.2)
n = 21 
9.6 
(2.4)
Lymph number (x10E9) n = 41 
14.9 
(11.3)
n = 14 
17.5 
(17.3)
n = 62 
12.5 
(12)
n = 24 
12.5 
(13.2)
n = 54 
16.1a 
(14.3)
n = 23 
24.1 
(16.5)
CrP (mg/L) n = 4 
27.3 
(37)
n = 1 
23 
(n/a)
n = 11 
45.9 
(106.8)
n = 5 
51.9 
(85.3)
n = 15 
8.5 
(12.6)
n = 7 
25.3 
(42.3)
Albumin (g/L) n = 24 
37.6 
(9.2)
n = 7 
40.4 
(3.6)
n = 38 
39.7 
(6.8)
n = 14 
35.6 
(17.1)
n = 32 
39.8 
(8.4)
n = 11 
39.1 
(10.4)
TiBC (µmol/L) n = 23 
59.2 
(13.3)
n = 7 
52.9 
(11.1)
n = 50 
55.3 
(12.6)
n = 18 
49.7 
(13.1)
n = 42 
59.6 
(11.8)
n = 17 
56.9 
(7.7)
Ferritin (µg/L) n = 22 
45.3 
(36)
n = 9 
39.7 
(24.4)
n = 50 
67.7 
(68.5)
n = 23 
94.3 
(183.3)
n = 45 
71.2 
(81.3)
n = 18 
42.2 
(41.7)
Note: astatistically significant difference between CD and UC 1 month pre-iFX (P , 0.02 from a Kruskal–Wallis test).
Abbreviations: CrP, C-reactive protein; hgb, hemoglobin; MPV, mean platelet volume; TiBC, total iron-binding capacity; WBC, white blood cell count.
infusion, hemoglobin was lower in UC than in CD patients 
(120.03 ± 18.3 vs 129.06 ± 18.1 g/L, respectively, P = 0.017). 
After infusions began, lymphocytes were lower in the CD 
group (CD , UC, 16.1 ± 14.3 vs 24.1 ± 16.5, P = 0.02).
Few C-reactive protein values were available, but, as 
expected, levels dropped in the period after IFX therapy. 
Only seven in both groups had C-reactive protein measured 
1 month before and at variable time intervals after. As an 
exercise, a nonparametric sign test showed a significant 
drop in these values after IFX had been started in patients 
continued on therapy (P = 0.016). This suggests that larger 
numbers of patients could have shown significant changes 
within each disease group as well.
In both groups, virtually all patients were started on IFX 
5 mg/kg (See Table 3). In CD patients, 83% were initiated 
because of severity of disease. Fistulae with or without activ-
ity were the indication in 16%, and other reasons were given 
in the rest (one patient). Indications were also severity of 
disease in UC for 81% of the cases. One UC patient with a 
rectovaginal fistula as the primary indication was otherwise 
well.
The yearly distribution of IFX initiation between 2000 and 
2008 is shown in Figure 1. There were 1214 infusions (999 
for CD and 215 for UC). The median infusions per patient 
was 12 (range 2–48) for CD and seven (range 2–32) for UC. 
For the entire group, the median time of follow-up based on 
length of treatment was 62 months. This is derived from the 
survival curve in Figure 2.
Although there were more infusions per CD patient 
than for UC (mean ± standard deviation [SD] 14.1 ± 11.2 vs 
8.6 ± 7.1 units, respectively, K–W P = 0.03), the yearly 
rate was similar (mean ± SD 11.2 ± 11.8 vs 9.9 ± 9.3 
infusions/year, K–W P = 0.9).
In the CD group, 55 (78%) had known inductive 
  infusions at 0, 2, and 6 weeks and 96% were infused on a 
regular basis. In this group, only two patients (3%) received Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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episodic infusions. In the UC group, 81% received triple 
induction infusions and 96% were regularly maintained. One 
patient (4%) received episodic infusion during the period of 
  observation. In both groups, 16% of the patient records were 
not clear as to scheduling of infusions.
There were no deaths during the observation period. In 
the entire group of 97 patients, only four (4%) serious side 
effects were listed. One UC patient was recorded as having 
a delayed lupus syndrome-like reaction. Other side effects 
included a combination of headaches, nausea, leg swelling, 
and sinusitis-like symptoms and led to discontinuation of 
IFX therapy. A higher rate of side effects in UC showed only 
a marginal significance (P = 0.061).
Characteristics of IFX treatment between CD and UC 
patients are shown in Table 4. Of the entire group, there 
were 17 primary failures (12 CD and five UC). Missing 
data resulted in failure to classify six patients (four CD and 
two UC). As a result, an overall response rate of 76% (77% 
CD and 73% UC) was observed.
Of the entire group, 54 (56%) patients met our defini-
tion of durable response (ongoing therapy without primary 
or Grade A failure). Of these, only one patient was started 
within 3 months of the end period. Therefore, 54% of the CD 
group and 62% of the UC group had durable responses. The 
summary of failures and responses are outlined in Table 4.
Of those patients who were continued on IFX (total 74: 55 
CD and 19 UC), a total of 12 (10 CD and two UC) required 
alternative forms of therapy. These included surgery (five 
CD patients), switching to adalimumab (four CD patients and 
one UC patient), and two other unspecified treatments (one 
CD patient and one UC patient). An additional six patients 
0%
2000 2002 2004 2006 2008 2000
Year of start of infliximab
2002 2004
CD UC
2006 2008
10%
20%
30%
40%
50%
Figure 1 The distribution of the number of infusions (by year) and year of start of iFX treatment by disease group are shown (n = 97). some patients who were tracked at 
infusion centers during the period of interest of the study began therapy earlier (also described in Methods).
Abbreviations: CD, Crohn’s disease; iFX, infliximab; UC, ulcerative colitis.
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Figure 2 Length of treatment for CD and/or UC is shown for the duration of the 
observational period of 76 months (log-rank P = 0.5; n = 97).
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Figure 3 survival analysis of CD (n = 9/52) and UC (n = 2/19) patients who 
developed Grade A failure (need to stop infliximab for medical reasons and alter 
therapy). Only patients who did not have primary failure were included, and three 
patients were missing sufficient data.
Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis.
Table 3 Characteristics of infliximab treatment for patients with 
Crohn’s disease (CD) and idiopathic ulcerative colitis (UC)
Crohn’s disease 
(n = 71)
Idiopathic 
ulcerative colitis 
(n = 26)
indications, n (%)
  severe disease only 55 (77.5%) 21 (80.8%)
  Fistula only 11 (15.5%) 1 (3.8%)
    Both severe disease 
and fistula
4 (5.6%) 0 (0%)
  Other 1 (1.4%) 4 (15.4%)
start dose
  5 mg/kg 69 (97.2%) 25 (96.2%)
  4 mg/kg 1 (1.4%) 0 (0%)
  Unknown 1 (1.4%) 1 (3.8%)
Total dose (mg) per patient, 
median (25th percentile,  
75th percentile)
350 (300, 400) 400 (300, 400)
infusions per patient,  
mean (sD)a
14.1 (11.2) 8.6 (7.1)
Total infusions for all patients 
with each disease
999 215
Note: aA statistical difference was noted only for the number of infusions per patient 
with CD . UC (P = 0.03 from a Kruskal–Wallis test).
Table 4 summary of therapeutic failures (primary and Grade A), 
adjustment requirements (Grade B), or ongoing therapy without 
primary or Grade A failure
Crohn’s disease 
(n = 71)
Idiopathic 
ulcerative colitis 
(n = 26)
Primary failure:
  no
  Yes
  Missing
 
55
12 (17% of 71)§
4
 
19
5 (19% of 26)§
2
Grade A failure among 
patients without primary 
failure:
  no
  Yes*
  Missing
n = 55 
 
 
43
10 (18% of 55)§§
2
n = 19
 
 
17
2 (11% of 19)
0
Grade B failure among 
patients without primary or 
Grade A failures:
  no
  Yes
n = 43
 
 
28
15 (35% of 43)†
n = 17
 
 
9
8 (47% of 17)‡
Ongoing therapy without 
primary or Grade A failures 
among all patients:
  no
  Yes
 
 
 
5
38 (54% of 71)
 
 
 
1
16 (62% of 26)
Notes: *Only five patients, all with CD, had both Grade B and Grade A failures 
and had to stop therapy subsequently. §One patient required surgery. §§Five patients 
required surgery. †Four of these patients stopped treatment. ‡One patient stopped 
treatment.
stopped IFX without meeting definitions of primary failure. 
The reasons included personal choice, fear of potential IFX 
side effects, or loss of financial coverage. For the entire 
group, 23 patients required frequency or dose adjustment 
(15 CD and eight UC).
Figure 3 shows survival analysis for Grade A failure (need 
to change therapy) for the patients without primary failure 
and with three patients excluded for missing data (log-rank 
P-value for the difference between groups = 0.86).
We conducted further analysis using logistic regres-
sion, with Grade A failure as the dichotomous outcome, 
among patients with CD who did not have primary failure. 
The   variables that we considered as predictive factors 
were age, time to disease, gender, and location (described 
in Table 1); laboratory values 1 month pre-IFX (described in 
Table 2); and any fistula and any severe disease (described 
in Table 3). The sample contained 53 CD patients without 
primary failure and known Grade A failure outcome, with 
10 patients who had Grade A failure. The sample sizes for 
the logistic regressions ranged from seven to 53 patients 
because of missing covariate data. When predictor fac-
tors were entered separately in logistic regression models, 
total iron-binding capacity at 1 month pre-IFX was the 
only significant   predictor of Grade A failure (P = 0.028). 
Models were not run for the UC patients, because only 
two UC patients had Grade A failure among those without 
primary failure.
Figure 4 shows survival analysis for any failure defined 
as either Grade A and/or Grade B (need to adjust therapy). 
The graph shows patients without primary failure and 
  excludes three with missing data. Five patients (all CD) with 
Grade A failure also had preceding Grade B failure. There Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Figure 4 survival analysis CD (n = 24/52) and UC (n = 10/19) patients who 
developed Grade A failure and/or Grade B failure (need to alter frequency or dose 
of infliximab therapy). Only patients who did not have primary failure were included, 
and three patients were missing data.
Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis.
was no significant difference between the survival curves for 
CD and UC patients (log-rank P-value = 0.14).
As an exercise, we also did an ad hoc log-rank analysis 
to determine whether the consumption of immunomodula-
tors anytime before and continued postinitiation of IFX 
impacted on durability of response. The addition of neither 
azathioprine/6-mercaptopurine (P = 0.87) nor methotrexate 
(P = 0.69) affected this parameter.
Discussion
This long-term retrospective comparison using IFX for 
mainly luminal CD and either moderately severe CD or UC 
highlights similarities between the two diseases. These are 
manifested by patterns of clinical and laboratory variables 
leading up to the start of infusion, response, and durability 
rates for longer time periods than currently published in 
controlled trials. Few serious side effects occurred leading 
to altering therapy with IFX.
We intended to evaluate patterns of medication use and 
laboratory values evolving toward biologic therapy and 
course after the start of treatment. There is some controversy 
as to whether the addition of immmunomodulators alters 
response to IFX. The original ACCENT I and II and ACT 
I and II trials did not establish the benefits of concomitant 
therapy.14–16,19 Similarly, the COMMIT (Combination of 
Maintenance Methotrexate-Infliximab Trial) evaluating 
methotrexate additional therapy with IFX for CD failed 
to find benefit.20 Others did observe that the addition of 
immunomodulators prior to IFX does help to maintain 
  duration of response, especially if started more than 3 months 
before.18 Furthermore, the SONIC (Study of Biologic and 
  Immunomodulator Naive Patients in Crohn’s Disease) 
  suggests that azathioprine/  6-mercaptopurine and IFX 
may induce steroid-free remission better than IFX alone.21 
Although we did not find that continuation of these drugs 
altered duration of response in this study, it was underpow-
ered. Therefore, the relatively high percentage observed in 
our report may still be explained by the addition of these 
drugs prior to IFX infusion.
Among laboratory parameters, it was of interest that albu-
min, total iron-binding capacity, and ferritin levels remained 
relatively stable in all three periods. Although perhaps of 
interest, total iron-binding capacity in the month before IFX 
infusion was the only univariate predictor of need to change 
therapy. However, no plausible explanation for this finding, 
other than perhaps chance, could be offered as to why it 
would be predictive. C-reactive protein was reduced follow-
ing IFX. However, too few values were available for reliable 
statistical comparisons. Elevated CRP levels prior to infusion 
improved by 4 weeks after therapy in another study.22
Outcome of therapy reflects published reports with some 
improvement. The ACCENT I study for luminally active 
CD showed a single infusion-induced remission in 58% of 
patients, and 39% and 45% were still in remission at the 
end of 46 weeks with either the 5 mg/kg or 10 mg/kg doses, 
respectively.14 The placebo response was 21%.   Similarly, 
the ACCENT II trial for treatment of fistulae in CD showed 
a sustained 36% response compared with 19% of placebo 
recipients after 54 weeks.15 A subsequent subanalysis 
reported short-term efficacy in rectovaginal fistulae as 
well.23 Treatment with IFX for CD reduced the need for 
  hospitalizations and surgery.20,24
In the case of UC, early reports indicated conflicting out-
comes, especially for rescue treatment to prevent   colectomy. 
Jarnerot et al reported that IFX significantly reduced risk of 
colectomy compared with 20% of placebo-treated patients.25 
A more recent retrospective study suggested that colectomy 
rates are moderately better with IFX,26 but another such 
study showed no salvage benefit to IFX.10 In the ACT I 
and II trials, 69% and 64% of UC patients, respectively, 
responded, and roughly similar outcomes as the ACCENT 
trials were reported at 54 weeks. The 5 mg/kg remission 
rate was 45% and the 10 mg/kg was 44% compared with 
placebo at 20%.16
In the current study, 76% of either group of patients 
responded and were higher than reported in randomized 
trials. In the two largest observational trials of CD patients, 
the Danish national survey and a Belgian single-center trial, 
82.7% and 89.2% responded, respectively.22,27 The reason Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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for these higher response rates is not entirely clear. The 
randomized trials had a more restricted definition of response. 
More received triple induction and more patients were on 
immunomodulators. These maneuvers may have helped to 
increase response rates.
In CD, a number of studies now have reported durabil-
ity of response beyond the original 52 weeks of randomized 
trials. The follow-up times ranged from 15 to 72 months 
with continued maintenance rates of 37%–66.4%.20,22,28,29 
Our study fits into the middle range of durability of these 
studies.
There are fewer reports on the long-term effects of 
IFX in UC. The largest number of cases was published by 
Ferrante et al from the group in Leuven, Belgium.30 Most 
of these patients were severe or moderately severe, and this 
study also covered a duration of 6 years. A response rate 
of 65% was reported, with two-thirds achieving a durable 
response. The concomitant use of immunomodulators did 
not influence outcome. The Danish national survey also 
included 17 UC patients; however, these were not analyzed 
separately.27 Our limited data suggest similar outcomes for 
patients with UC as those with CD.
The frequency of side effects was low and similar to the 
Danish27 report and the study by Rudolph et al.20 Rates were 
higher in the study from Belgium.22 A possible explanation 
for our low severe side effect rate may be explained by the 
fact that the majority of both groups of patients were already 
taking immunomodulators before starting IFX. This might 
limit infusion reactions and protect against side effects, as 
was noted in the Danish study.27 Similarly, regular infu-
sions likely reduced anti-TNFα chimeric antibodies and 
reactions.24 Finally, the relative youth of both groups may 
have been protective.
Several weaknesses in our report need to be addressed. 
The first is that few patients were included in the cohort. 
The effect of this is that any subtle differences in outcome 
of treatment between CD and UC may be missed. However, 
with very few exceptions (like side effects), there were no 
trends observed, and the differences found between groups 
were negligible. Second, pouchitis is sometimes classified 
as a separate entity, but its pathogenesis is putatively a con-
tinuation of the overall process in UC,31,32 and it is doubtful 
that its inclusion (about 8% of total UC) would impact 
on outcome. Thirdly, we had difficulty ascertaining some 
variables, especially after IFX. For example, classifying 
severity of disease before was based on the referring physi-
cian’s opinion and, following therapy, assessment was also 
limited. Similarly, evaluation of other therapy after IFX was 
severely limited. As a result, we are unable to specifically 
comment on the outcome of those patients who were steroid 
nonresponsive or dependent and clearly delineate withdrawal 
of other immunomodulators. Finally, minor infusion reac-
tions and need for premedication were not clearly defined. 
However, knowledge of these facts would not appreciably 
alter overall outcome.
In summary, we report a retrospective review of the 
  pattern of use and outcome of IFX therapy over a 6-year 
period in a group of moderately severe CD and UC patients. 
The study suggests similar effects of IFX in both diseases 
and shows durability and relative safety over an extended 
time period.
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